中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 38 Issue 11
Nov.  2022
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(11): 2483-2487

Expression of autophagy marker in peripheral blood T and B lymphocytes of patients with autoimmune hepatitis and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2022.11.009

  • Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

Beijing Advanced Innovation Center for Big Data-Based Precision Medicine (PXM2021-014226-000026);

Capital's Funds for Health Improvement and Research (2021-1G-2181);

Incubation Project for Young and Middle-Aged Talents of Beijing YouAn Hospital, Capital Medical University (YNKTQN2021008)

More Information
  • Corresponding author: DUAN Zhongping, duan@ccmu.edu.cn(ORCID: 0000-0002-2188-9692)
  • Received Date: 2022-04-26
  • Accepted Date: 2022-05-30
  • Published Date: 2022-11-20
    Abstract
  •   Objective  To investigate the expression of autophagy marker in peripheral blood T and B lymphocytes of patients with autoimmune hepatitis (AIH) and its clinical significance.  Methods  Peripheral blood samples were collected from 62 AIH patients who were treated in Beijing YouAn Hospital affiliated to Capital Medical University from October 2019 to October 2020 who were treated in Beijing YouAn Hospital affiliated to Capital Medical University from October 2019 to October 2020 and 8 healthy controls to detect autophagy of T and B lymphocyte subsets, and then subgroup analyses were performed based on treatment, diagnostic type, and presence or absence of liver cirrhosis and liver failure. The t-test was used for comparison of normally distributed continuous data between two groups; the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups, and the Mann-Whitney U test was used for comparison between two groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between two groups.  Results  Compared with the healthy control group, the AIH group had a significantly higher mean fluorescence intensity (MFI) of the autophagy marker LC3B in CD4+ T, CD8+ T, CD19+ B, and CD4+CD25+ T lymphocytes (all P < 0.05), especially in CD19+ B lymphocytes. The non-treatment group and the partial remission group had a significantly higher MFI of autophagy marker in CD19+ B lymphocytes than the complete remission group (P=0.037 and 0.040); the idiopathic AIH (I-AIH) group and the drug-induced AIH(DI-AIH) group had a significantly higher MFI than the primary biliary cholangitis (PBC)-AIH overlap syndrome group (P=0.037 and 0.031); the non-cirrhosis group and the decompensated cirrhosis group had a significantly higher MFI than the compensated cirrhosis group (P=0.009 and 0.003); the liver failure group had a significantly higher MFI than the non-liver failure group (P=0.042). The PBC-AIH group had a significantly higher MFI of autophagy marker in CD4+CD25+ T lymphocytes than the I-AIH group and the DI-AIH group (P=0.042 and 0.044), the compensated cirrhosis group had a significantly lower MFI than the non-cirrhosis group (P=0.037), and the non-liver failure group had a significantly higher MFI than the liver failure group (P=0.043).  Conclusion  AIH patients have a significant increase in the expression of autophagy marker in peripheral blood T and B lymphocyte subsets compared with healthy individuals, and the level of autophagy is associated with treatment, diagnostic type, and disease severity.

     

    • FullText(HTML)
    • References(22)
  • [1]
    LIBERAL R, de BOER YS, ANDRADE RJ, et al. Expert clinical management of autoimmune hepatitis in the real world[J]. Aliment Pharmacol Ther, 2017, 45(5): 723-732. DOI: 10.1111/apt.13907.
    [2]
    ALVAREZ F, BERG PA, BIANCHI FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5): 929-938. DOI: 10.1016/s0168-8278(99)80297-9.
    [3]
    HENNES EM, ZENIYA M, CZAJA AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology (Baltimore, Md), 2008, 48(1): 169-176. DOI: 10.1002/hep.22322.
    [4]
    WEILER-NORMANN C, SCHRAMM C. Drug induced liver injury and its relationship to autoimmune hepatitis[J]. J Hepatol, 2011, 55(4): 747-749. DOI: 10.1016/j.jhep.2011.02.024.
    [5]
    YEONG TT, LIM KH, GOUBET S, et al. Natural history and outcomes in drug-induced autoimmune hepatitis[J]. Hepatol Res, 2016, 46(3): E79-E88. DOI: 10.1111/hepr.12532.
    [6]
    CHAZOUILLÈRES O, WENDUM D, SERFATY L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy[J]. Hepatology, 1998, 28(2): 296-301. DOI: 10.1002/hep.510280203.
    [7]
    BOBERG KM, CHAPMAN RW, HIRSCHFIELD GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue[J]. J Hepatol, 2011, 54(2): 374-385. DOI: 10.1016/j.jhep.2010.09.002.
    [8]
    SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3.
    [9]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [10]
    FUKUI H, SAITO H, UENO Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015[J]. J Gastroenterol, 2016, 51(7): 629-650. DOI: 10.1007/s00535-016-1216-y.
    [11]
    LEBINE B, MIZUSHIMA N, VIRGIN HW. Autophagy in immunity and inflammation[J]. Nature, 2011, 469(7330): 323-335. DOI: 10.1038/nature09782.
    [12]
    WANG WR, TANG XD. Research progress of autophagy in the prevention and treatment of malignant hematologic diseases[J]. China Med Herald, 2021, 18(33): 35-39. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202133008.htm

    王文儒, 唐旭东. 自噬在恶性血液病防治过程中的研究进展[J]. 中国医药导报, 2021, 18(33): 35-39. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202133008.htm
    [13]
    WU DJ, ADAMOPOULOS IE. Autophagy and autoimmunity[J]. Clin Immunol, 2017, 176: 55-62. DOI: 10.1016/j.clim.2017.01.007.
    [14]
    CHEN YW, WANG C, WANG XG, et al. Levels of autophagy in T cells and B cell of patients with systemic lupus erythematosus and its clinical significance[J]. Chin J Immunol, 2015, 31(10): 1380-1384. DOI: 10.3969/j.issn.1000-484X.2015.10.018.

    陈燕文, 王超, 王旭光, 等. 系统性红斑狼疮患者外周血T、B细胞自噬水平及其临床意义[J]. 中国免疫学杂志, 2015, 31(10): 1380-1384. DOI: 10.3969/j.issn.1000-484X.2015.10.018.
    [15]
    CLARKE AJ, ELLINGHAUS U, CORTINI A, et al. Autophagy is activated in systemic lupus erythematosus and required for plasmablast development[J]. Ann Rheum Dis, 2015, 74(5): 912-920. DOI: 10.1136/annrheumdis-2013-204343.
    [16]
    HAMPE CS. B cell in autoimmune diseases[J]. Scientifica (Cairo), 2012, 2012: 215308. DOI: 10.6064/2012/215308.
    [17]
    BRANDÃO DF, RAMALHO FS, MARTINELLI AL, et al. Relationship between plasma cells and hepatic stellate cells in autoimmune hepatitis[J]. Pathol Res Pract, 2010, 206(12): 800-804. DOI: 10.1016/j.prp.2010.08.002.
    [18]
    RADBRUCH A, MUEHLINGHAUS G, LUGER EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell[J]. Nat Rev Immunol, 2006, 6(10): 741-750. DOI: 10.1038/nri1886.
    [19]
    CARO-MALDONADO A, WANG R, NICHOLS AG, et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells[J]. J Immunol, 2014, 192(8): 3626-3636. DOI: 10.4049/jimmunol.1302062.
    [20]
    TORIGOE M, IWATA S, NAKAYAMADA S, et al. Metabolic reprogramming commits differentiation of human CD27+IgD+ B cells to plasmablasts or CD27-IgD- cells[J]. J Immunol, 2017, 199(2): 425-434. DOI: 10.4049/jimmunol.1601908.
    [21]
    PENGO N, SCOLARI M, OLIVA L, et al. Plasma cells require autophagy for sustainable immunoglobulin production[J]. Nat Immunol, 2013, 14(3): 298-305. DOI: 10.1038/ni.2524.
    [22]
    RAZA I, CLARKE AJ. B cell metabolism and autophagy in autoimmunity[J]. Front Immunol, 2021, 12: 681105. DOI: 10.3389/fimmu.2021.681105.
    • Relative Articles

  • Relative Articles

    [1]Runbing ZHANG, Tingting SHI, Yang WU, Jiucong ZHANG, Xiaofeng ZHENG. The mechanism of autophagy inducing drug resistance of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(11): 2315-2319. doi: 10.12449/JCH241128
    [2]Yuesheng LIAO, Lili BAI. Role of exercise-induced autophagy in prevention and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(5): 1156-1160. doi: 10.3969/j.issn.1001-5256.2022.05.038
    [3]Wendi DONG, Hairong ZHANG, Rui LI, Yuyan ZHANG, Jie ZHU. Role of regulatory T/T helper 17 cells in the pathogenesis of autoimmune hepatitis and related therapeutic targets[J]. Journal of Clinical Hepatology, 2021, 37(10): 2456-2460. doi: 10.3969/j.issn.1001-5256.2021.10.042
    [4]Qianlan DAI, Shaoneng LIU. Role of autophagy in liver fibrosis[J]. Journal of Clinical Hepatology, 2021, 37(6): 1440-1444. doi: 10.3969/j.issn.1001-5256.2021.06.046
    [5]Peiwei YANG, Guangwei LIU, Wenxia ZHAO. Mechanism of autophagy in the development and progression of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2021, 37(11): 2689-2691. doi: 10.3969/j.issn.1001-5256.2021.11.044
    [6]Han ZhiWei, Wang ZongYu, Ju JiaNi, Li KeZhi, Wu GuoBin, Lin DongYi, Chen Chuang. Regulatory effect of water extract of Jianpi Xiaoji prescription on autophagy of human liver cancer SMMC7721 cells[J]. Journal of Clinical Hepatology, 2020, 36(3): 587-591. doi: 10.3969/j.issn.1001-5256.2020.03.023
    [7]Wang YuLu, Xu XiaoYang, Yu XiaoHan, Ping Jian, Zhao ChangQing. Role of oxidative stress and autophagy in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(2): 426-429. doi: 10.3969/j.issn.1001-5256.2020.02.042
    [8]Liang LiMin, Xu HeXiang, Zheng JiShun, Zhang YuanYuan. Value of neutrophil-lymphocyte ratio in predicting the prognosis of patients with decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(4): 790-795. doi: 10.3969/j.issn.1001-5256.2019.04.017
    [9]Zhou ZhenHua, Wang LingTai, Gao YueQiu. Role of hepatocyte mitophagy in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(12): 2809-2811. doi: 10.3969/j.issn.1001-5256.2019.12.036
    [10]Wu YanBin, Wang XueWen, Niu HongKai, Cheng Yu. Research advances in the role of protective autophagy in regulating vasculogenic mimicry formation in malignancies such as cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2019, 35(8): 1882-1884. doi: 10.3969/j.issn.1001-5256.2019.08.053
    [11]Gong Jing, Jie XinKe. Effect of endoplasmic reticulum stress and autophagy on hepatocyte apoptosis[J]. Journal of Clinical Hepatology, 2019, 35(12): 2828-2832. doi: 10.3969/j.issn.1001-5256.2019.12.041
    [12]Wang MuQi, Li YaPing, Liu LaYang, Dang ShuangSuo, Shi JuanJuan, Jia XiaoLi. Role and mechanism of autophagy in development and progression of hepatocellular carcinoma and regulation of immunotherapy[J]. Journal of Clinical Hepatology, 2019, 35(5): 1129-1134. doi: 10.3969/j.issn.1001-5256.2019.05.045
    [13]Wu DuJuan, Jin Lei, Gao YuFeng, Ye Jun, Xia GuoMei, Li Fang, Zou GuiZhou. Value of neutrophil-lymphocyte ratio in evaluating the short-time prognosis of patients with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2018, 34(9): 1945-1949. doi: 10.3969/j.issn.1001-5256.2018.09.023
    [14]Yan Rong, Niu ChunYan, Yu Lu, Tian Yu. Interaction between autophagy and lipid metabolism in cell models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(10): 1981-1986. doi: 10.3969/j.issn.1001-5256.2017.10.027
    [15]Jiang Na, Ping Jian, Xu LieMing. Research advances in the role of autophagy in liver cells and regulation of MAPK pathway[J]. Journal of Clinical Hepatology, 2016, 32(5): 1009-1012. doi: 10.3969/j.issn.1001-5256.2016.05.048
    [16]Zhu XueMin, Meng QingHua. Hepatocyte autophagy model established by physical method[J]. Journal of Clinical Hepatology, 2016, 32(8): 1566-1570. doi: 10.3969/j.issn.1001-5256.2016.08.027
    [17]Wang WeiHao, Xu WeiHua. Roles of Nrf2 and autophagy in liver fibrosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 447-451. doi: 10.3969/j.issn.1001-5256.2015.03.033
    [18]Huang LanYu, Xu LieMing. Relationship between liver diseases and autophagy[J]. Journal of Clinical Hepatology, 2014, 30(2): 186-188. doi: 10.3969/j.issn.1001-5256.2014.02.022
    [19]Ding JianBo, Li XiuHui. Current perspectives on the role of autophagy in liver fibrosis[J]. Journal of Clinical Hepatology, 2013, 29(4): 305-307.
    [20]Guo JinSheng. Recent perspectives on mechanisms of liver fibrogenesis: microRNA and cell autophagy [J]. Journal of Clinical Hepatology, 2013, 29(5): 324-326.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(4)

    1. 李亚芹，张荣臻，严惠萍，韦荣明，吴智鹏，王明刚，李海洋. 细胞自噬与肝衰竭的发生发展. 中西医结合肝病杂志. 2024(10): 945-948 .
    2. 陈克岩，吴婷，杨灿. T淋巴细胞线粒体损伤指数在自身免疫性肝炎患者中的临床意义及影响因素. 肝脏. 2024(11): 1409-1412+1426 .
    3. 杨峰，李爱梅，王聪. 酒精性肝病失代偿期肝硬化患者腹水和外周血淋巴细胞亚群的特征及临床意义. 中国医师杂志. 2023(11): 1682-1686 .
    4. 蔡文杰，何敏，李同文. 自身免疫性肝病早期外周血RDW、ADA及补体水平的检测意义. 锦州医科大学学报. 2023(06): 62-65 .

    Other cited types(0)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 12.3 %FULLTEXT: 12.3 %META: 82.0 %META: 82.0 %PDF: 5.7 %PDF: 5.7 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.4 %其他: 7.4 %其他: 0.6 %其他: 0.6 %Russian Federation: 0.1 %Russian Federation: 0.1 %Seattle: 0.1 %Seattle: 0.1 %Taoyuan District: 0.2 %Taoyuan District: 0.2 %[]: 0.6 %[]: 0.6 %三亚: 0.1 %三亚: 0.1 %上海: 1.1 %上海: 1.1 %中卫: 0.6 %中卫: 0.6 %中央邦: 0.3 %中央邦: 0.3 %临沂: 0.2 %临沂: 0.2 %丹东: 0.1 %丹东: 0.1 %乌鲁木齐: 0.1 %乌鲁木齐: 0.1 %佛山: 0.1 %佛山: 0.1 %信阳: 0.1 %信阳: 0.1 %内江: 0.1 %内江: 0.1 %北京: 6.5 %北京: 6.5 %南京: 0.2 %南京: 0.2 %南宁: 0.2 %南宁: 0.2 %南昌: 0.2 %南昌: 0.2 %南阳: 0.1 %南阳: 0.1 %卡纳塔克: 0.1 %卡纳塔克: 0.1 %厦门: 0.1 %厦门: 0.1 %台州: 2.0 %台州: 2.0 %吉林: 0.8 %吉林: 0.8 %呼和浩特: 0.3 %呼和浩特: 0.3 %咸阳: 0.4 %咸阳: 0.4 %哥伦布: 0.1 %哥伦布: 0.1 %天津: 0.2 %天津: 0.2 %太原: 0.3 %太原: 0.3 %安庆: 0.1 %安庆: 0.1 %安康: 0.1 %安康: 0.1 %宣城: 0.2 %宣城: 0.2 %常德: 0.2 %常德: 0.2 %广州: 0.7 %广州: 0.7 %廊坊: 0.1 %廊坊: 0.1 %张家口: 3.2 %张家口: 3.2 %成都: 6.5 %成都: 6.5 %无锡: 0.2 %无锡: 0.2 %日照: 0.1 %日照: 0.1 %昆明: 0.6 %昆明: 0.6 %昌吉: 0.1 %昌吉: 0.1 %晋中: 0.1 %晋中: 0.1 %朝阳: 0.2 %朝阳: 0.2 %杭州: 0.7 %杭州: 0.7 %柏林: 0.3 %柏林: 0.3 %武汉: 0.5 %武汉: 0.5 %汕头: 0.1 %汕头: 0.1 %江门: 0.2 %江门: 0.2 %沈阳: 0.1 %沈阳: 0.1 %济南: 0.3 %济南: 0.3 %济宁: 0.1 %济宁: 0.1 %海得拉巴: 0.3 %海得拉巴: 0.3 %湖州: 0.4 %湖州: 0.4 %湘潭: 0.1 %湘潭: 0.1 %潍坊: 0.2 %潍坊: 0.2 %潮州: 0.1 %潮州: 0.1 %福州: 0.2 %福州: 0.2 %绍兴: 0.1 %绍兴: 0.1 %绵阳: 0.1 %绵阳: 0.1 %罗奥尔凯埃: 0.1 %罗奥尔凯埃: 0.1 %芒廷维尤: 19.9 %芒廷维尤: 19.9 %苏州: 0.1 %苏州: 0.1 %莫斯科: 1.4 %莫斯科: 1.4 %蚌埠: 0.1 %蚌埠: 0.1 %衢州: 0.5 %衢州: 0.5 %西宁: 29.3 %西宁: 29.3 %西安: 0.4 %西安: 0.4 %诺沃克: 0.5 %诺沃克: 0.5 %贵阳: 0.3 %贵阳: 0.3 %费利蒙: 0.1 %费利蒙: 0.1 %辽源: 0.1 %辽源: 0.1 %运城: 1.2 %运城: 1.2 %郑州: 0.4 %郑州: 0.4 %鄂州: 0.2 %鄂州: 0.2 %重庆: 0.2 %重庆: 0.2 %金华: 0.1 %金华: 0.1 %银川: 0.1 %银川: 0.1 %镇江: 0.1 %镇江: 0.1 %长春: 3.4 %长春: 3.4 %长沙: 0.4 %长沙: 0.4 %随州: 0.1 %随州: 0.1 %青岛: 0.4 %青岛: 0.4 %香港: 0.2 %香港: 0.2 %其他其他Russian FederationSeattleTaoyuan District[]三亚上海中卫中央邦临沂丹东乌鲁木齐佛山信阳内江北京南京南宁南昌南阳卡纳塔克厦门台州吉林呼和浩特咸阳哥伦布天津太原安庆安康宣城常德广州廊坊张家口成都无锡日照昆明昌吉晋中朝阳杭州柏林武汉汕头江门沈阳济南济宁海得拉巴湖州湘潭潍坊潮州福州绍兴绵阳罗奥尔凯埃芒廷维尤苏州莫斯科蚌埠衢州西宁西安诺沃克贵阳费利蒙辽源运城郑州鄂州重庆金华银川镇江长春长沙随州青岛香港

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (773) PDF downloads(54) Cited by(4)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2151]YesterdayPV[4214]TodayIP[485]TodayPV[911]Online[100]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return